{"filing":{"accession_number":"0000313143-26-000118","cik":"0000313143","ticker":"HAE","company_name":"HAEMONETICS CORP","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"hae-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000118/hae-20260806.htm"},"events":[{"id":25333,"run_id":22984,"accession_number":"0000313143-26-000118","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Haemonetics issued a press release on August 6, 2026 announcing first quarter fiscal 2027 financial results, including revenue of $339.4 million (up 5.6%), earnings per diluted share of $0.72, and adjusted EPS of $1.14. The company also raised its full-year fiscal 2027 guidance for reported revenue growth (5-8%) and organic revenue growth (4-7%). This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02.","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26128,"accession_number":"0000313143-26-000118","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Haemonetics issued a press release on August 6, 2026 announcing first quarter fiscal 2027 financial results, including revenue of $339.4 million (up 5.6%), earnings per diluted share of $0.72, and adjusted EPS of $1.14. The company also raised its full-year fiscal 2027 guidance for reported revenue growth (5-8%) and organic revenue growth (4-7%). This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:32:47.897076+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26128,"accession_number":"0000313143-26-000118","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Haemonetics issued a press release on August 6, 2026 announcing first quarter fiscal 2027 financial results, including revenue of $339.4 million (up 5.6%), earnings per diluted share of $0.72, and adjusted EPS of $1.14. The company also raised its full-year fiscal 2027 guidance for reported revenue growth (5-8%) and organic revenue growth (4-7%). This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:32:47.897076+00:00","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-08-06"}]}